William M. Stauffer, MD, MSPH; Jonathan D. Alpern, MD; Patricia F. Walker, MD, DTM&H
has active quiz
JAMA. 2020;324(7):623-624. doi:10.1001/jama.2020.13170
Anticipating widespread global use of dexamethasone for COVID-19 in the wake of RECOVERY trial findings, this Viewpoint summarizes the theoretical risk of triggering Strongyloides hyperinfection/dissemination syndrome in people with asymptomatic strongyloidiasis, and proposes an algorithm to for assessing and managing the risk in outpatient and hospital settings.
Robert M. Califf, MD; Adrian F. Hernandez, MD, MHS; Martin Landray, MBChB
has active quiz
JAMA. 2020;324(7):625-626. doi:10.1001/jama.2020.13319
This Viewpoint discusses the role of observational study designs and data in the rapid stand-up of an evidence base for managing the COVID-19 pandemic, proposing ways to position observational research as a foundation for rapid follow-on randomized evaluation without premature overinterpretation of its findings.
Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research
Steven N. Goodman, MD, MHS, PhD; Sebastian Schneeweiss, MD, ScD; Michael Baiocchi, PhD
Jan M. Friedman, MD, PhD; Kenneth Lyons Jones, MD; John C. Carey, MD, MPH
JAMA. 2020;324(7):627-628. doi:10.1001/jama.2020.11126
This Viewpoint describes indications and proper clinical use and interpretation of exome sequencing, explaining that the testing is not diagnostic in itself but requires correlation with patients’ history and presentation in the context of a comprehensive clinical evaluation.
Conversations with Dr Bauchner:
Exome Sequencing and Clinical Diagnosis
Ned Calonge, MD; Lisa Brown, MPH; Autumn Downey, PhD
JAMA. 2020;324(7):629-630. doi:10.1001/jama.2020.12901
This Viewpoint summarizes recommendations from a 2020 National Academies of Sciences, Engineering, and Medicine (NASEM) report on transforming the infrastructure, funding, and methods of public health emergency preparedness and response (PHEPR) research to ensure it is grounded in the best science about what works where, why, and for whom.
David C. Grossman, MD, MPH; Eric B. Larson, MD, MPH; Harold C. Sox, MD
JAMA. 2020;324(7):631-632. doi:10.1001/jama.2020.1406
This Viewpoint discusses genome-wide sequencing (GWS) as a potential pathway not only to personalized medicine but also to population health, and proposes 5 dimensions health care organizations might consider when deciding on markers to screen for as they move toward genomic approaches to caring for their patient populations.